Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bausch HealthFRA:BVF +1.49%65 EV-to-EBIT is 26.02 as of Aug. 05, 2026, which is 52% above its 10-year median of 17.07. GuruFocus rates FRA:BVF with a GF Score™ of 65/100 and a GF Value™ of €6.20 (Fairly Valued). The stock has 3 warning signs investors should review. Among 690 Drug Manufacturers companies, Bausch Health ranks worse than 68.99% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bausch Health's Enterprise Value for the quarter that ended in Jun. 2026 was €18,789 Mil.
Bausch Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €746 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch Health EV-to-EBIT Related Terms
Bausch Health EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Bausch Health's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch Health EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bausch Health's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bausch Health's EV-to-EBIT falls into.
Bausch Health's current Enterprise Value is €19,412 Mil.
Bausch Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €746 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch Health (FRA:BVF) has a EV-to-EBIT of 26.02 as of Aug. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bausch Health and its competitors. This is 52% above median its historical median of 17.07. According to the industry distribution chart, Bausch Health ranks #476 out of 690 companies in the Drug Manufacturers industry, placing it in the top 69%.
Is Bausch Health's EV-to-EBIT too high?
Bausch Health's current EV-to-EBIT of 26.02 is 52% above median its 10-year median of 17.07. The Drug Manufacturers industry median EV-to-EBIT is 15.57. Bausch Health's value of 26.02 is 67.1% above this industry median. Based on the distribution chart, Bausch Health ranks #476 out of 690 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bausch Health has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bausch Health ranks #476 out of 690 companies for EV-to-EBIT. This places Bausch Health in the lower half of its industry. The industry median EV-to-EBIT is 15.57. Bausch Health's value of 26.02 is 67.1% above this benchmark. While the company's 10-year median is 17.07 vs. the industry median of 15.57, Bausch Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.57, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bausch Health's current EV-to-EBIT of 26.02 is 67.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bausch Health and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch Health's current EV-to-EBIT is 26.02, which is 52% above median its own 10-year median of 17.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Based on GuruFocus' analysis, Bausch Health (FRA:BVF) is currently considered Fairly Valued. The stock's GF Value™ is €6.20, compared to a current price of €5.81 — trading 6.4% below its estimated fair value. The current EV-to-EBIT is 26.02, which is 52% above median its 10-year median of 17.07 and 67.1% above the Drug Manufacturers industry median of 15.57. Bausch Health's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bausch Health (FRA:BVF), the current EV-to-EBIT is 26.02 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch Health (FRA:BVF) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued.
The current stock price of €5.81 is trading 6.4% below its estimated GF Value™ of €6.20.
GuruFocus considers Bausch Health to be Fairly Valued.
Key valuation signals for FRA:BVF:
EV-to-EBIT: 26.02 (52% above median its 10-year median of 17.07)
GF Value™: €6.20 vs. price of €5.81 (6.4% below fair value)
Industry Position: 67.1% above the Drug Manufacturers median (#476 of 690)
No single metric tells the full story. See the FRA:BVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
65GF Score
Get the complete analysis for FRA:BVF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BVF has been successfully added to your 
